Flash glucose monitoring is associated with small but sustained improvements in glycemic control and a reduction in severe hypoglycemia relative to self-monitoring of blood glucose in type 1 diabetes, observational data show.
The amount of carbohydrate needed to treat mild or moderate hypoglycemia in people with type 1 diabetes using a predictive low-glucose suspend system may be considerably lower than what is currently recommended, report researchers.
Phase 2 study results suggest that add-on treatment with an anti-IL-21 antibody plus liraglutide could preserve endogenous insulin secretion in people with recent-onset type 1 diabetes.